Prof. Dr. rer. nat. hab. Renata Stripecke
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation and REBIRTH Excellence Cluster
Rebuilding the immune system after cancer or transplantation requires the regeneration of adaptive immune responses by dendritic cells. A new generation of engineered dendritic cells that can be induced with designed lentiviral vectors is proposed, which is current in development as an advanced therapy medicinal product. This technology was evaluated in models in vitro, in immunocompetent mice and in humanized mice and was adapted for a two-days GMP-compliant standard operating procedure for clinical trials.